These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
172 related items for PubMed ID: 4468026
1. Experimental and clinical study on the antituberculous activity of tuberactinomycin-N, a new antibiotic. Toyoara M. Bull Int Union Tuberc; 1974 Aug; 49 suppl 1():288-91. PubMed ID: 4468026 [No Abstract] [Full Text] [Related]
2. [Studies on tuberactinomycin-N. Report 3. Comparison of the effects of TUM-N and INH on experimental mouse tuberculosis (author's transl)]. Shimizu T, Yokoyama M, Yoshida U, Onuma H, Narita A. Kekkaku; 1977 Jan; 52(1):21-7. PubMed ID: 839648 [No Abstract] [Full Text] [Related]
4. [The effects of tuberactinomycin-N (TUM-N) for severe pulmonary tuberculosis (author's transl)]. Miwa T, Tsukamura M, Majima T, Ando Y, Kotetsu Y. Kekkaku; 1975 Aug; 50(8):229-33. PubMed ID: 1195529 [No Abstract] [Full Text] [Related]
5. [Clinical study of enviomycin (EVM) in pulmonary tuberculosis (author's transl)]. Kuramitsu I, Ando K, Ito N, Kishimoto K, Murase Y, Matsumura H, Matsui O, Miki S, Ito T, Yanagawa T, Tanaka S, Sakai M, Takeuchi J, Yamamoto Y, Suzuki S, Sata K, Ohbori K, Horie E, Sakurai K, Mori T, Nagami T, Adachi S, Oda T, Yamaguchi K, Takehisa R. Kekkaku; 1978 Apr; 53(4):269-73. PubMed ID: 661060 [No Abstract] [Full Text] [Related]
6. [A study on therapeutic effects of enviomycin in retreatment for drug resistant pulmonary tuberculosis (author's transl)]. Kondo K, Kuze A, Sato S, Kurematu S, Tateno S, Shimizu T, Arima J, Yamamoto KI, Obara H, Hiraga H, Takada N, Kon Y, Takagi H, Kakinoki H, Mituka M, Ueda S, Takayama K, Ueda N, Kuwajima T, Sakai Y, Hamano E, Aikawa K, Hasegawa S, Abe M, Tanaka M, Yokoyama Y, Suzuki A. Kekkaku; 1979 May; 54(5):303-8. PubMed ID: 480779 [No Abstract] [Full Text] [Related]
10. [An experimental study of the chemotherapeutic efficacy of flurenizid, a new antitubercular pharmaceutical]. Khomenko AG, Golyshevskaia VI, Maslova LI, Kalmykova GN, Uvarova OA. Probl Tuberk; 1990 May; (6):3-7. PubMed ID: 2217100 [Abstract] [Full Text] [Related]
11. [Tuberculosis]. Bonnaud F, Zigani A. Rev Prat; 2002 Oct 15; 52(16):1809-20. PubMed ID: 12564174 [No Abstract] [Full Text] [Related]
12. [Original treatment of pulmonary tuberculosis by enviomycin (EVM)]. Ogiwara S. Kekkaku; 1987 Sep 15; 62(9):459-67. PubMed ID: 2828742 [No Abstract] [Full Text] [Related]
13. Older antibiotic gains new respect as potent treatment for tuberculosis. Rifapentine is already approved for use with humans. Nuermberger E. Home Healthc Nurse; 2008 Apr 15; 26(4):204-5. PubMed ID: 18408506 [No Abstract] [Full Text] [Related]
16. [Experimental studies in vitro on the antituberculous activities of tuberactinomycin (TUM) and tuberactinomycin-N (TUM-N) (author's transl)]. Maekawa N, Ikeda N, Oda Y, Uratsuji Y, Inagake H. Kekkaku; 1977 May 15; 52(5):211-8. PubMed ID: 407391 [No Abstract] [Full Text] [Related]
20. [Study on the antituberculous activity of Tuberactin, a new antibiotic]. Toyohara M. Kekkaku; 1968 Jul 15; 43(7):245-8. PubMed ID: 5727835 [No Abstract] [Full Text] [Related] Page: [Next] [New Search]